These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
477 related articles for article (PubMed ID: 27233604)
1. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells. Tripathi S; Srivastava G; Sharma A Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604 [TBL] [Abstract][Full Text] [Related]
2. Structural investigations into the binding mode of novel neolignans Cmp10 and Cmp19 microtubule stabilizers by in silico molecular docking, molecular dynamics, and binding free energy calculations. Tripathi S; Kumar A; Kumar BS; Negi AS; Sharma A J Biomol Struct Dyn; 2016 Jun; 34(6):1232-40. PubMed ID: 26212016 [TBL] [Abstract][Full Text] [Related]
3. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594 [TBL] [Abstract][Full Text] [Related]
4. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. Gonzalez-Garay ML; Chang L; Blade K; Menick DR; Cabral F J Biol Chem; 1999 Aug; 274(34):23875-82. PubMed ID: 10446152 [TBL] [Abstract][Full Text] [Related]
5. Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach. Verma K; Ramanathan K J Cell Biochem; 2015 Jul; 116(7):1318-24. PubMed ID: 25735511 [TBL] [Abstract][Full Text] [Related]
6. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies. Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655 [TBL] [Abstract][Full Text] [Related]
7. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability. Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091 [TBL] [Abstract][Full Text] [Related]
8. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Mukhtar E; Adhami VM; Sechi M; Mukhtar H Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140 [TBL] [Abstract][Full Text] [Related]
9. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects. Churchill CD; Klobukowski M; Tuszynski JA Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329 [TBL] [Abstract][Full Text] [Related]
10. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672 [TBL] [Abstract][Full Text] [Related]
11. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer. Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021 [TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid. Yin S; Cabral F; Veeraraghavan S Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of the chiral centers of Taxol on binding to β-tubulin: A docking and molecular dynamics simulation study. Ghadari R; Alavi FS; Zahedi M Comput Biol Chem; 2015 Jun; 56():33-40. PubMed ID: 25854803 [TBL] [Abstract][Full Text] [Related]
14. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. Kamath K; Wilson L; Cabral F; Jordan MA J Biol Chem; 2005 Apr; 280(13):12902-7. PubMed ID: 15695826 [TBL] [Abstract][Full Text] [Related]
15. The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments. Churchill CD; Klobukowski M; Tuszynski JA Chem Biol Drug Des; 2015 Aug; 86(2):190-9. PubMed ID: 25376845 [TBL] [Abstract][Full Text] [Related]
16. Microtubules and resistance to tubulin-binding agents. Kavallaris M Nat Rev Cancer; 2010 Mar; 10(3):194-204. PubMed ID: 20147901 [TBL] [Abstract][Full Text] [Related]
17. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes. Kumbhar BV; Panda D; Kunwar A PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771 [TBL] [Abstract][Full Text] [Related]
18. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401 [TBL] [Abstract][Full Text] [Related]
19. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach. Kumbhar BV; Bhandare VV; Panda D; Kunwar A J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055 [TBL] [Abstract][Full Text] [Related]
20. Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. Cheung CH; Wu SY; Lee TR; Chang CY; Wu JS; Hsieh HP; Chang JY PLoS One; 2010 Sep; 5(9):e12564. PubMed ID: 20838440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]